1. Home
  2. FMY vs VERU Comparison

FMY vs VERU Comparison

Compare FMY & VERU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo First Trust Motgage Income Fund of Beneficial Interest

FMY

First Trust Motgage Income Fund of Beneficial Interest

N/A

Current Price

$11.43

Market Cap

49.0M

Sector

Finance

ML Signal

N/A

Logo Veru Inc.

VERU

Veru Inc.

N/A

Current Price

$2.76

Market Cap

45.0M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
FMY
VERU
Founded
2005
1971
Country
United States
United States
Employees
N/A
N/A
Industry
Finance/Investors Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
49.0M
45.0M
IPO Year
2005
1996

Fundamental Metrics

Financial Performance
Metric
FMY
VERU
Price
$11.43
$2.76
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$22.50
AVG Volume (30 Days)
2.6K
241.0K
Earning Date
01-01-0001
05-12-2026
Dividend Yield
6.98%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$16,296,958.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$11.40
$2.05
52 Week High
$12.38
$7.33

Technical Indicators

Market Signals
Indicator
FMY
VERU
Relative Strength Index (RSI) 39.70 56.44
Support Level N/A $2.12
Resistance Level $11.80 $2.87
Average True Range (ATR) 0.12 0.11
MACD -0.01 0.02
Stochastic Oscillator 1.91 66.18

Price Performance

Historical Comparison
FMY
VERU

About FMY First Trust Motgage Income Fund of Beneficial Interest

First Trust Mortgage Income Fund is a United States-based diversified, closed-end management investment company. The fund's primary investment objective is to seek a high level of current income. Its secondary investment objective is to preserve capital. The fund pursues its objectives by investing predominantly in mortgage-backed securities representing part ownership in a pool of either residential or commercial mortgage loans that, in the opinion of the Fund's investment advisor, offer an attractive combination of credit quality, yield, and maturity.

About VERU Veru Inc.

Veru Inc is a late clinical-stage biopharmaceutical focused on developing medicines for the treatment of cardiometabolic and inflammatory diseases. Its drug development program consists of two late-stage new chemical entities, enobosarm and sabizabulin. Enobosarm, an oral selective androgen receptor modulator, is being developed to make weight reduction by GLP-1 RA drugs more tissue selective for loss of fat and preservation of lean mass, and is planned for a Phase 2b PLATEAU clinical study in obesity. Sabizabulin, an oral microtubule disruptor, is being developed for the treatment of inflammation in atherosclerotic cardiovascular disease to lower high-sensitivity CRP in patients with stable coronary artery disease, with a planned Phase 2 study.

Share on Social Networks: